SURVYR

RVTY

Revvity, Inc.
$157.36
+$0.75 (0.48%)Oct 22 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-16%+6%+28%+50%+72%Oct 2025Oct 2026Apr 202652w high $166.2552w low $81.22
RVTYSPY
Wall St. Highest PT $175.00 (+11.2%) Wall St. Avg PT $147.53 (-6.2%)
$82$107$131$156$180POC $96Hi $175Avg $148
Underwater Drawdown %Max DD -30.1%Current 0.0%
0.0%-30.1%
Relative Strength vs SPY+47.7% vs SPYOutperforming
+55%0%-55%
1W
+$2.65 (1.71%)
1M
+$14.05 (9.80%)
3M
+$44.19 (39.05%)
6M
+$70.26 (80.68%)
YTD
+$60.80 (62.97%)
1Y
+$61.87 (64.80%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
15 analysts · mean score 2.39
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$157.36
Average target$147.53
−$9.83 (−6.2%) downsideaverage target vs current price
CurrentAverageMedian
Low$110.00
Median$147.53
High$175.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-13 · TD Cowen reiterated Buy on RVTY
Reiterated
2026-10-07 · Barclays reiterated Equal-Weight on RVTY
Initiated
2026-10-06 · William Blair started covering RVTY at Outperform
Reiterated
2026-09-04 · Keybanc reiterated Overweight on RVTY
Initiated
2026-09-01 · RBC Capital started covering RVTY at Sector Perform
Reiterated
2026-08-05 · Evercore ISI Group reiterated Outperform on RVTY
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$17.6B
P/E (last 12 months)74.9
P/E (next 12 months, estimated)26.7
52-week range$81.22 – $166.25
Revenue growth (latest quarter vs a year ago)+1.3%
Dividend yield0.18%
Analyst consensusBuy (15)
Average analyst price target$147.53 (-6%)

What they do

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
83rd percentile in sector
A-
12-1 return: +63.7%
Percentile within its GICS sector across the S&P 1500.
Growth
15th percentile in sector
D-
Revenue growth (YoY): +1.3%
Percentile within its GICS sector across the S&P 1500.
Value
24th percentile in sector
D+
Forward E/P: 3.9% · EBITDA/EV: 4.5%
Percentile within its GICS sector across the S&P 1500.
Profitability
41st percentile in sector
C
Profit margin: +8.2% · Return on equity: +3.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 69 of 499 · 12-month momentum 47.2%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RVTY earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$1.30 range $1.28–$1.33
Revenue consensus$694.7M 15 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026$1.41est $1.22+15.9%Above estimates
May 5, 2026$1.06est $1.01+4.5%Above estimates
Feb 2, 2026$1.70est $1.58+7.8%Above estimates
Oct 27, 2025$1.18est $1.14+3.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-22 21:45:38 ET
24-1125-0125-0425-0725-1026-0226-0526-080.001.70
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$729.7M+1.3%
2026-03-31$711.1M–
2025-12-31$772.1M–
2025-09-30$698.9M–
2025-06-30$720.3M–

Recent dividends

2026-07-17: $0.070 · 2026-04-17: $0.070 · 2026-01-16: $0.070 · 2025-10-17: $0.070 · 2025-07-18: $0.070 · 2025-04-17: $0.070 · 2025-01-17: $0.070 · 2024-10-18: $0.070

News & catalysts

More news
Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
Business Wire · Oct 20
Rating changes
Reiterated
2026-10-13 · TD Cowen reiterated Buy on RVTY
Reiterated
2026-10-07 · Barclays reiterated Equal-Weight on RVTY
Initiated
2026-10-06 · William Blair started covering RVTY at Outperform
Reiterated
2026-09-04 · Keybanc reiterated Overweight on RVTY
Initiated
2026-09-01 · RBC Capital started covering RVTY at Sector Perform
Reiterated
2026-08-05 · Evercore ISI Group reiterated Outperform on RVTY

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-22 21:45:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026